Inverse Relationship between the Contents of Neuromelanin Pigment and the Vesicular Monoamine Transporter-2: Human Midbrain Dopamine Neurons

Journal of Comparative Neurology

Volumn 473, Issue 1, 2004, Pages 97-106

  Liang, Chang Lin ^a   Nelson, Omar ^a   Yazdani, Umar ^a   Pasbakhsh, Parichehr ^a,b   German, Dwight C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Nigrosome 1; Parkinson's disease; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

DOPAMINE; NEUROMELANIN; TYROSINE 3 MONOOXYGENASE;

ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MESENCEPHALON; NERVE CELL DEGENERATION; NEUROTRANSMISSION; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SUBSTANTIA NIGRA; SYNAPSE VESICLE; VENTRAL TEGMENTUM;

ADULT; AGED; AGED, 80 AND OVER; DOPAMINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MELANINS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MESENCEPHALON; MIDDLE AGED; MODELS, NEUROLOGICAL; NEURONS; NEUROPEPTIDES; PIGMENTS, BIOLOGICAL; POSTMORTEM CHANGES; TYROSINE 3-MONOOXYGENASE; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 1942517416     PISSN: 00219967     EISSN: None     Source Type: Journal    
DOI: 10.1002/cne.20098     Document Type: Article

References (47)

1. Bean AJ, Roth RH. 1991. Extracellular dopamine and neurotensin in rat prefrontal cortex in vivo: effects of median forebrain bundle stimulation frequency, stimulation pattern, and dopamine autoreceptors. J Neurosci 11:2694-2702.
2. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
3. Cheramy A, Leviel V, Glowinski J. 1981. Dendritic release of dopamine in the substantia nigra. Nature 289:537-542.
4. Conway KA, Rochet J-C, Bieganski RM, Lansbury PT Jr. 2001. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α -synuclein adduct. Science 294:1346-1349.
5. D'Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Snyder SH. 1987. Neuromelanin: a role in MPTP-induced neurotoxicity. Life Sci 40:705-712.
6. Damier P, Hirsch EC, Agid Y, Graybiel AM. 1999a. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin-D28k immunohistochemistry. Brain 122:1421-1436.
7. Damier P, Hirsch EC, Agid Y, Graybiel AM. 1999b. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122:1437-1448.
8. Del Zompo M, Piccardi MP, Ruiu S, Quartu M, Gessa GL, Vaccari A. 1993. Selective uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. Br J Pharmacol 109:411-414.
9. Ellis RJ. 2001. Macromolecular crowding: an important but neglected aspect of the intracellular environment. Curr Opin Struct Biol 11:114-119.
10. Enochs WS, Sarna T, Zecca L, Riley PA, Swartz HM. 1994. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis. J Neural Transm Parkinson Dis Dement Sect 7:83-100.
11. Falkenburger BH, Barstow KL, Mintz IM. 2001. Dendrodendritic inhibition through reversal of dopamine transport. Science 293:2465-2470.
12. Gainetdinov RR, Fumagalli F, Wang Y-M, Jones SR, Levey AI, Miller GW, Caron MG. 1998. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygous knockout mice. J Neurochem 70: 1973-1978.
13. German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. 1989. Dopamine cell loss in Parkinson's disease: computer visualization. Ann Neurol 26:507-514.
14. German DC, Liang CL, Manaye KF, Lane K, Sonsalla PK. 2000. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. Neuroscience 101:1063-1069.
15. Grace AA, Bunney BS. 1984. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4:2877-2890.
16. Graham DG. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643.
17. Graham DG. 1979. On the origin and significance of neuromelanin. Arch Pathol Lab Med 103:359-362.
18. Hassler R. 1939. Zur pathologischen anatomie des senilen und des parkinsonistichen tremor. J Psychol Neurol 49:13-55.
19. Hirsch E, Graybiel AM, Agid YA. 1988. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-348.
20. 14C]diquat in frogs and mice: accumulation in neuromelanin. Neurosci Lett 93:1-6.
21. Liu Y, Edwards RH. 1997. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci 20:125-156.
22. Mann DMA, Yates PO. 1979. The effects of ageing on the pigmented nerve cells of the human locus coeruleus and substantia nigra. Acta Neuropathol 47:83-97.
23. Mann DMA, Yates PO. 1982. Aging, nucleic acids and pigments. In: Thomas-Smith W, Cavanagh JB, editors. Recent advances in neuropathology, vol 2. London: Churchill-Livingston. p 109-138.
24. Mann DMA, Yates PO. 1983. Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Ageing Dev 21:193-203.
25. McCormack AL, Delfani K, Janson AM, Langston JW, Di Monte DA. 2001. Neuronal vulnerability to MPTP injury: roles of aging and neuromelanin. Soc Neurosci Abstr 31:386.
26. Nirenberg MJ, Chan J, Liu Y, Edwards RH, Pickel VM. 1996. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somadendritic storage and release of dopamine. J Neurosci 16:4135-4145.
27. Parker WD Jr, Swerdlow RH. 1998. Mitochondrial electron-transport-chain dysfunction in Parkinson's disease (PD) Am J Hum Genet 62: 758-762.
28. Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, Cookson MR. 2002. Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36: 1007-1019.
29. Pothos EN, Larsen KE, Krantz DE, Liu Y-J, Haycock JM, Setlik W, Gershon ME, Edwards RH, Sulzer D. 2000. Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J Neurosci 20:7297-7306.
30. Reinhard JF Jr, Diliberto EJ, Humberto Viveros O, Daniels AJ. 1987. Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci U S A 84:8160-8164.
31. Reinhard JF Jr, Carmichcael SW, Danniels AJ. 1990. Mechanisms of toxicity and cellular resistance to 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in adrenomedullary chromaffin cell cultures. J Neurochem 55:311-320.
32. Sanghera MK, Manaye KF, Liang CL, Iacopino AM, Bannon MJ, German DC. 1994. Low dopamine transporter mRNA levels in midbrain regions containing calbindin. Neuroreport 5:1641-1644.
33. Shepard PD, German DC. 1988. Electrophysiological and pharmacological evidence for the existence of distinct subpopulations of nigrostriatal dopaminergic neuron in the rat. Neuroscience 27:537-546.
34. Sherer TB, Kim J-H, Betarbet R, Greenamyre JT. 2003. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregations. Exp Neurol 179:9-16.
35. Shima T, Sarna T, Swartz HM, Stroppolo A, Gerbasi R, Zecca L. 1997. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Rad Biol Med 23:110-119.
36. Shtilerman MD, Ding TT, Lansbury PT. 2002. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry 41:3855-3860.
37. Sonsalla PK, Manzino L, Sinton CM, Liang C-L, German DC, Zeevalk GD. 1997. Inhibition of striatal energy metabolism produces cell loss in the ipsilateral substantia nigra. Brain Res 773:223-226.
38. + is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience 84:1177-1185.
39. Sulzer D, Bugulavshy J, Larsen KE, Behr G, Karatekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L. 2000. Neuromelanin biosynthesis by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A 97:11869-11874.
40. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, Uhl GR. 1997. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion and enhanced MPTP toxicity. Proc Natl Acad Sci U S A 94:9938-9943.
41. Thibaut F, Faucheux BA, Marquez J, Villares J, Menard JF, Agid Y, Hirsch EC. 1995. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Brain Res 692:233-243.
42. Uversky VN, Cooper EM, Bower KS, Li J, Fink AL. 2002. Accelerated α-synuclein fibrillation in crowded milieu. FEBS Lett 515:99-103.
43. 3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 68:955-962.
44. Vyas I, Heikkila RE, Nicklas WJ. 1986. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J Neurochem 46:1501-1507.
45. Xu J, Kao S-Y, Lee FJ-S, Song W, Jin L-W, Yankner BA. 2002. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nat Med 8:600-606.
46. Zecca L, Pietra R, Goj C, Mecacci C, Radice D, Sabbioni E. 1994. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J Neurochem 62:1097-1101.
47. Zeevalk GD, Derr-Yellin E, Nicklas WJ. 1995. Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. J Pharmacol Exp Ther 275: 1124-1130.